News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EU Approves Merck KGaA (MKGAF.PK)'s Erbitux For A Subtype Of Cancer


12/23/2013 7:21:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The European Commission has approved the use of Merck KGaA (MRK.XE) drug Erbitux for treatment of a subtype of cancer, the German pharmaceutical company said Monday. MAIN FACTS: - The Commission has approved an update of the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer. - The approval follows the positive opinion from the Committee for Medicinal Products for Human Use.

Help employers find you! Check out all the jobs and post your resume.

Read at Nasdaq


comments powered by Disqus
Nasdaq
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES